In the third PDAC used in proteomic analysis, C3L-01158, percent of KRAS VAF of 2.7% in bulk, 4.4% in cored, and 17.3% in LMD tumor tissues were observed, respectively, representing 5.4%, 8.8%, and 34.6% neoplastic cellularity in the bulk, cored, and LMD tumors (Table 1). This evidence concerns the gene KRAS and neoplasm.